[HTML][HTML] Nitric oxide (NO): an emerging target for the treatment of glaucoma

ME Cavet, JL Vittitow, F Impagnatiello… - … & visual science, 2014 - tvst.arvojournals.org
The predominant risk factor for the progression of glaucoma is an increase in IOP, mediated
via a reduction in aqueous outflow through the conventional (trabecular meshwork and …

Molecular genetics of glaucoma: Subtype and ethnicity considerations

R Zukerman, A Harris, A Verticchio Vercellin, B Siesky… - Genes, 2020 - mdpi.com
Glaucoma, the world's leading cause of irreversible blindness, is a complex disease, with
differential presentation as well as ethnic and geographic disparities. The multifactorial …

Vascular and autonomic dysregulation in primary open-angle glaucoma

LR Pasquale - Current opinion in ophthalmology, 2016 - journals.lww.com
Overall, POAG is likely a heterogeneous disease but stratifying cases by IOP level
associated with initial optic nerve damage may be less useful than using other …

Pharmacological regulation of outflow resistance distal to Schlemm's canal

F McDonnell, WM Dismuke… - American Journal of …, 2018 - journals.physiology.org
The trabecular meshwork (TM) and Schlemm's canal generate the majority of outflow
resistance; however, the distal regions of the conventional outflow pathway account for 25 …

The nitric oxide-guanylate cyclase pathway and glaucoma

LK Wareham, ES Buys, RM Sappington - Nitric Oxide, 2018 - Elsevier
Glaucoma is a prevalent optic neuropathy characterized by the progressive dysfunction and
loss of retinal ganglion cells (RGCs) and their optic nerve axons, which leads to irreversible …

Association of CAV1/CAV2 genomic variants with primary open-angle glaucoma overall and by gender and pattern of visual field loss

SJ Loomis, JH Kang, RN Weinreb, BL Yaspan… - Ophthalmology, 2014 - Elsevier
Purpose The CAV1/CAV2 (caveolin 1 and caveolin 2) genomic region previously was
associated with primary open-angle glaucoma (POAG), although replication among …

Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension

PL Kaufman - Expert Opinion on Pharmacotherapy, 2017 - Taylor & Francis
ABSTRACT Introduction: Intraocular pressure (IOP)-lowering has been demonstrated to
slow the progression or onset of visual field loss in open-angle glaucoma (OAG) or ocular …

Is estrogen a therapeutic target for glaucoma?

SS Dewundara, JL Wiggs, DA Sullivan… - Seminars in …, 2016 - Taylor & Francis
This article's objective is to provide an overview of the association between estrogen and
glaucoma. A literature synthesis was conducted of articles published in peer-reviewed …

Association of gene polymorphisms with primary open angle glaucoma: a systematic review and meta-analysis

M Chen, X Yu, J Xu, J Ma, X Chen… - … & visual science, 2019 - iovs.arvojournals.org
Methods: We searched in PubMed and Web of Science (up to January 10, 2018) for genetic
studies of POAG. All case control studies investigating the association between single …

Shear stress in Schlemm's canal as a sensor of intraocular pressure

F McDonnell, KM Perkumas, NE Ashpole, J Kalnitsky… - Scientific reports, 2020 - nature.com
Elevated intraocular pressure (IOP) narrows Schlemm's canal (SC), theoretically increasing
luminal shear stress. Using engineered adenoviruses containing a functional fragment of the …